Over $2M in Investments Using Reg A+ Mini-IPO to Advance Non-Opioid Pain Drug Candidate into Clinical Trials December 14, 2018 InSitu Biologics Press No comments yet WOODBURY, Minn., Dec. 4, 2018 /Press Release/ — InSitu Biologics, Inc., an emerging biotech company focusing on the development of AnestaGel™, has received over $2 million in […] Read more